The Cost of Cancer Care at the End of Life: Implications for Centers for Medicare and Medicaid Services and for Radiation Oncology.

[1]  H. Sandler,et al.  Recent Trends in Medicare Payments for Outpatient Cancer Care at the End of Life. , 2022, International journal of radiation oncology, biology, physics.

[2]  T. Bathala,et al.  Definitive Local Consolidative Therapy for Oligometastatic Solid Tumors: Results from the Lead-In Phase of the Randomized Basket Trial EXTEND. , 2022, International journal of radiation oncology, biology, physics.

[3]  B. Yaremko,et al.  Stereotactic Radiation for the Comprehensive Treatment of Oligometastases (SABR-COMET) - Extended Long-Term Outcomes. , 2022, International journal of radiation oncology, biology, physics.

[4]  E. Bruera,et al.  Duration of palliative care involvement and immunotherapy treatment near the end of life among patients with cancer who died in-hospital , 2022, Supportive Care in Cancer.

[5]  S. Loi,et al.  Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma-The RAPPORT Trial. , 2021, European urology.

[6]  S. Vinod,et al.  Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II): The Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical Trial. , 2021, JAMA oncology.

[7]  E. Goetghebeur,et al.  PEACE V – Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): a study protocol for a randomized controlled phase II trial , 2020, BMC Cancer.

[8]  B. Yaremko,et al.  Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial , 2020, medRxiv.

[9]  S. Gilbertson-White,et al.  Immune Checkpoint Inhibitor Use Near the End of Life: A Single-Center Retrospective Study. , 2019, Journal of palliative medicine.

[10]  A. Kishan,et al.  Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease , 2019, BMC Cancer.

[11]  V. Khoo,et al.  TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney - FASTRACK II , 2018, BMC Cancer.

[12]  J. Lee,et al.  Local Consolidative Therapy versus Maintenance Therapy/Observation for Patients with Oligometastatic Non-Small Cell Lung Cancer without Progression after Front-Line Systemic Therapy: Results of a Multi-Institutional Phase II Randomized Study , 2016, The Lancet. Oncology.

[13]  Ehud Mendel,et al.  Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. , 2011, International journal of radiation oncology, biology, physics.

[14]  R. Schilsky,et al.  Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.